Quantcast

Latest Regulus Therapeutics Stories

2014-11-06 16:35:40

LA JOLLA, Calif., Nov. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.

2014-11-05 16:30:38

- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated - LA JOLLA, Calif., Nov.

2014-11-03 08:30:46

CARLSBAD, Calif., Nov. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.

2014-10-30 16:29:15

LA JOLLA, Calif., Oct. 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.

2014-10-28 20:24:05

LA JOLLA, Calif., Oct.

2014-10-27 16:27:52

LA JOLLA, Calif., Oct.

2014-10-22 08:31:10

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct.

2014-10-14 08:32:24

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients- LA JOLLA, Calif.,

2014-10-09 08:27:08

CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related